You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

somatostatin analogue

Showing 1 - 25 of 1,830
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Satisfaction With Somatostatin Analogue Injections in Acromegaly

Not yet recruiting
  • Acromegaly
    • (no location specified)
    Aug 9, 2022

    Neuroendocrine Tumors Trial in Meldola (177Lu-DOTATATE 25.9 GBq activity, 177Lu-DOTATATE 18.5 GBq activity)

    Active, not recruiting
    • Neuroendocrine Tumors
    • 177Lu-DOTATATE 25.9 GBq activity
    • 177Lu-DOTATATE 18.5 GBq activity
    • Meldola, FC, Italy
      Irst Irccs
    Feb 25, 2021

    Malignant Carcinoid Syndrome Trial in Tampa (lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR)

    Terminated
    • Malignant Carcinoid Syndrome
    • lanreotide Autogel (somatostatin analogue)
    • Sandostatin long acting release (LAR) Depot (somatostatin analogue)
    • Tampa, Florida
      Larry Kvols, MD
    Apr 28, 2020

    Acromegaly Trial in Worldwide (Paltusotine)

    Completed
    • Acromegaly
    • Los Angeles, California
    • +44 more
    Jul 27, 2021

    Colon Cancer, Colo-rectal Cancer Trial in Assiut, Buraidah (Cetuximab nanoparticles, Oral approved anticancer drug)

    Unknown status
    • Colon Cancer
    • Colo-rectal Cancer
    • Cetuximab nanoparticles
    • Oral approved anticancer drug
    • Assiut, Egypt
    • +3 more
    Oct 9, 2019

    Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

    Recruiting
    • SSTR2-positive Tumors
    • 177Lu-LNC1010 1
    • +2 more
    • Xiamen, China
      The First Affiliated Hospital of Xiamen University
    Nov 20, 2022

    High Grade Glioma, Meningioma, Embryonal Tumor Trial in United States (LUTATHERA® (Lutetium Lu 177 dotatate))

    Recruiting
    • High Grade Glioma
    • +12 more
    • LUTATHERA® (Lutetium Lu 177 dotatate)
    • Aurora, Colorado
    • +8 more
    Jan 16, 2023

    Obesity, Hypoglycemia, Surgery Trial in Aarhus C (Oral Glucose tolerance test (OGGT), Liquid mixed meal, Octreotide)

    Completed
    • Obesity
    • +2 more
    • Oral Glucose tolerance test (OGGT)
    • +2 more
    • Aarhus C, Denmark
      Department of Endocrinology, Aarhus University Hospital
    Oct 24, 2019

    Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor

    Recruiting
    • PET / CT
    • +3 more
    • 68Ga-DOTA-TATE PET/MR and PET/CT imaging
    • Wuhan, Hubei, China
      China, Hubei Province
    Apr 26, 2022

    Pancreatic Diseases Trial in Rochester (Somatostatin analog)

    Enrolling by invitation
    • Pancreatic Diseases
    • Somatostatin analog
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Apr 21, 2022

    Factors Associated With Significant MYoCArdian Uptake on

    Not yet recruiting
    • Oncologic Disorders
      • (no location specified)
      Jul 26, 2022

      Neuroendocrine Tumors Trial in Beijing (177Lu-DOTA-EB-TATE 1, 177Lu-DOTA-TATE, 177Lu-DOTA-EB-TATE 2)

      Unknown status
      • Neuroendocrine Tumors
      • 177Lu-DOTA-EB-TATE 1
      • +3 more
      • Beijing, China
        Peking Union Medical College Hospital
      Jul 6, 2019

      Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)

      Active, not recruiting
      • Neuroendocrine Carcinoma
      • Lu-DOTA-TATE
      • London, Ontario, Canada
        London Health Sciences Centre
      Apr 5, 2022

      Hepatic Carcinoma, Hepatic Metastasis Trial in Pamplona (Octreotide, Placebo)

      Recruiting
      • Hepatic Carcinoma
      • Hepatic Metastasis
      • Pamplona, Spain
        Clinica Universidad de Navarra
      Oct 10, 2023

      Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)

      Not yet recruiting
      • Neuroendocrine Tumors
      • Portland, Oregon
        Providence Portland Cancer Institute - Franz Clinic
      Feb 10, 2022

      Meningioma Trial in Basel (177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and

      Recruiting
      • Meningioma
      • 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
      • +2 more
      • Basel, Basel-Stadt, Switzerland
        University Hospital Basel, Department of Neurosurgery
      Aug 2, 2021

      Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,

      Not yet recruiting
      • Neuroendocrine Neoplasia's (NENs)
      • Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
      • Basel, Switzerland
        Division of Nuclear Medicine, University Hospital Basel
      Apr 27, 2022

      Pancreatic Surgery Trial in Paris (Somatostatin, Octreotide)

      Completed
      • Pancreatic Surgery
      • Paris, France
      • +1 more
      Apr 30, 2021

      Non-variceal Gastrointestinal Bleeding Trial in Cairo (PPI group, PPI plus octreotide)

      Recruiting
      • Non-variceal Gastrointestinal Bleeding
      • PPI group
      • PPI plus octreotide
      • Cairo, Egypt
        NHTMRI
      Sep 28, 2023

      Neuroendocrine Tumor Trial in Houston (AlphaMedix)

      Recruiting
      • Neuroendocrine Tumor
      • Houston, Texas
      • +1 more
      Aug 17, 2021

      Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor Trial in São Paulo (Tamoxifen)

      Active, not recruiting
      • Neuroendocrine Tumors
      • +2 more
      • Tampa, Florida
      • +1 more
      Jan 13, 2023

      Neuroendocrine Tumors Trial in Riyadh (Everolimus)

      Unknown status
      • Neuroendocrine Tumors
      • Riyadh, Saudi Arabia
        Oncology Centre, King Faisal Specialist Hospital & Research Cent
      Aug 9, 2018

      Neuroendocrine Tumors Trial in Seoul (Lanreotide autogel)

      Recruiting
      • Neuroendocrine Tumors
      • Lanreotide autogel
      • Seoul, Korea, Republic of
        Changhoon Yoo
      Jul 18, 2022

      Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT) Trial in Ferrara (Lutetium-177 (177Lu)-DOTATOC, Yttrium-90

      Recruiting
      • Neuroendocrine Tumors
      • Peptide Receptor Radionuclide Therapy (PRRT)
      • Lutetium-177 (177Lu)-DOTATOC
      • +4 more
      • Ferrara, Italy
        University Hospital of Ferrara
      Mar 5, 2021

      GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease Trial in United States

      Recruiting
      • GEP-NET
      • +6 more
      • Duarte, California
      • +3 more
      Jul 28, 2022